Cell Signaling Technology

Product Pathways - Translational Control

PKR Antibody #3072

Applications Reactivity Sensitivity MW (kDa) Source
W IP H Endogenous 74 Rabbit

Applications Key:  W=Western Blotting  IP=Immunoprecipitation
Reactivity Key:  H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

PKR Antibody detects endogenous levels of PKR. This antibody does not cross-react with other related proteins.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Thr451 of human PKR. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from HeLa cells, untreated or IFN-alpha/beta-treated (1000 U/ml for 18 hours), and subsequently untreated or calyculin A-treated ( 0.1 µM for 15 minutes), using PKR Antibody.

Background

Protein kinase R (PKR) is transcriptionally induced by interferon and activated by double-stranded RNA (dsRNA). PKR inhibits translation initiation through phosphorylation of the α subunit of the initiation factor eIF2 (eIF2α) and also controls the activation of several transcription factors, such as NF-κB, p53, and the Stats. In addition, PKR mediates apoptosis induced by many different stimuli, such as LPS, TNF-α, viral infection, and serum starvation (1,2). Activation of PKR by dsRNA results in PKR dimerization and autophosphorylation of Thr446 and Thr451 in the activation loop. Substitution of threonine for alanine at position 451 completely inactivated PKR, while a mutant with a threonine to alanine substitution at position 446 was partially active (3). Research studies have implicated PKR activation in the pathologies of neurodegenerative diseases, including Alzheimer's disease (4,5).

  1. Williams, B.R. (1999) Oncogene 18, 6112-6120.
  2. Gil, J. and Esteban, M. (2000) Apoptosis 5, 107-114.
  3. Romano, P. R. et al. (1998) Mol. Cell. Biol. 18, 2282-2297.
  4. Peel, A.L. and Bredesen, D.E. (2003) Neurobiol. Dis. 14, 52-62.
  5. Peel, A.L. (2004) J. Neuropath. Exp. Neurol. 63, 97-105.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products